Show simple item record

dc.contributor.authorKumar, Anil
dc.contributor.authorZavadskasb, Edmundas Kazimieras
dc.contributor.authorMangla, Sachin Kumar
dc.contributor.authorAgrawal, Varun
dc.contributor.authorSharma, Kartik
dc.contributor.authorGupta, Divyanshu
dc.date.accessioned2018-11-21T19:00:50Z
dc.date.available2018-11-21T19:00:50Z
dc.date.issued2018-11-19
dc.identifier.citationKumar, A., Zavadskasb, E.K., Mangla, S.K., Agrawal, V., Sharma, K. and Gupta, D. (2018) 'When risks need attention: adoption of green supply chain initiatives in the pharmaceutical industry', International Journal of Production Researchen
dc.identifier.urihttp://hdl.handle.net/10545/623142
dc.description.abstractThe pharmaceutical industry is very important in delivering life-saving products/services to society. There are many ways for materials/products/services concerned with pharmaceuticals to influence the environment; these include improper disposal of pills/tablets by patients, expired and unused medications, improper release of drugs by pharmacies or household sewage mixed with surplus drugs. In view of this, the present work seeks to integrate green supply chain (GSC) concepts in the pharmaceutical sector in a developing economy Indian context. In so doing, managers need to determine the potential risks in adopting GSC initiatives to achieve sustainability in operational perspectives. In this sense, this work seeks to distinguish the potential risks in adopting GSC initiatives within the pharmaceutical industry. This work uses a literature review and fuzzy Delphi approach in finalising the risks. This research also uses fuzzy Analytical Hierarchy Process (AHP) for prioritisation of the risks under vague and unclear surroundings. According to the findings, cold chain technology and supply risks categories are highly prioritised. This work can assist practising managers and government authorities in effectively developing and managing GSC initiatives in line with sustainable development goals in the context of the pharmaceutical industry. Finally, a sensitivity test is applied to evaluate the stability of ranking of risks.
dc.description.sponsorshipN/Aen
dc.language.isoenen
dc.publisherTaylor & Francisen
dc.relation.urlhttps://www.tandfonline.com/doi/full/10.1080/00207543.2018.1543969en
dc.subjectRisken
dc.subjectGreen Supply Chainen
dc.subjectPharmaceutical industryen
dc.subjectSustainable Productionen
dc.subjectFuzzy Delphien
dc.subjectFuzzy AHPen
dc.titleWhen risks need attention: adoption of green supply chain initiatives in the pharmaceutical industryen
dc.typeArticleen
dc.contributor.departmentUniversity of Derbyen
dc.contributor.departmentVilnius Gediminas Technical Universityen
dc.contributor.departmentUniversity of Plymouthen
dc.contributor.departmentBML Munjal Universityen
dc.identifier.journalInternational Journal of Production Researchen
dc.date.accepted2018-10-26
html.description.abstractThe pharmaceutical industry is very important in delivering life-saving products/services to society. There are many ways for materials/products/services concerned with pharmaceuticals to influence the environment; these include improper disposal of pills/tablets by patients, expired and unused medications, improper release of drugs by pharmacies or household sewage mixed with surplus drugs. In view of this, the present work seeks to integrate green supply chain (GSC) concepts in the pharmaceutical sector in a developing economy Indian context. In so doing, managers need to determine the potential risks in adopting GSC initiatives to achieve sustainability in operational perspectives. In this sense, this work seeks to distinguish the potential risks in adopting GSC initiatives within the pharmaceutical industry. This work uses a literature review and fuzzy Delphi approach in finalising the risks. This research also uses fuzzy Analytical Hierarchy Process (AHP) for prioritisation of the risks under vague and unclear surroundings. According to the findings, cold chain technology and supply risks categories are highly prioritised. This work can assist practising managers and government authorities in effectively developing and managing GSC initiatives in line with sustainable development goals in the context of the pharmaceutical industry. Finally, a sensitivity test is applied to evaluate the stability of ranking of risks.


Files in this item

Thumbnail
Name:
Revised Manuscript.pdf
Embargo:
2019-11-20
Size:
197.7Kb
Format:
PDF
Description:
Post Print

This item appears in the following Collection(s)

Show simple item record